Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamol
AssigneeEli Lilly and Company
InventorsJohn Michael BEALS, Eric Dwayne HAWKINS, Anthony Shane RANSDELL, Shantanu Virendra SULE, Monica Rixman SWINNEY
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical insulin compositions comprising insulin, a preservative, and at least one selected from the group consisting of aspirin, acetaminophen, dexamethasone, heparin, meloxicam, bromfenac sodium, salicylic acid; and the use of the compositions to treat diabetes.
Claims76
A pharmaceutical composition comprising insulin, a preservative, and at least one agent selected from the group consisting of meloxicam, bromfenac sodium, acetylsalicylic acid, salicylic acid, dexamethasone, heparin, and paracetamol.
A pharmaceutical composition comprising:
- a. insulin;
- b. zinc, in a concentration from about 0.2 mM to about 1 mM;
- c. a preservative;
- d. at least one agent selected from the group consisting of meloxicam, bromfenac sodium, acetylsalicylic acid, salicylic acid, and paracetamol.
A pharmaceutical composition comprising:
- a. insulin lispro, in a concentration from about 100 to about 200 U/mL;
- b. zinc, in a concentration from about 0.2 mM to about 1 mM;
- c. m-cresol, in a concentration from about 2.5 to about 3.8 mg/mL;
- d. at least one agent selected from the group consisting of meloxicam, bromfenac sodium, acetylsalicylic acid, salicylic acid, and paracetamol;
- and;
- e. having a pH of about 7.0 to about 7.8 at room temperature.
A pharmaceutical composition comprising:
- a. insulin lispro, in a concentration of about 200 IU/mL;
- b. zinc, in a concentration of about 0.8 mM;
- c. m-cresol, in a concentration of about 3.15 mg/mL;
- and
- d. at least one agent selected from the group consisting of salicylic acid. and acetaminophen.
Dependencies are inferred from the claim text.